Cover Image

Current and emerging treatment options in triple-negative breast cancer

Omer Dizdar, Kadri Altundag
  • Omer Dizdar
    Department of Medical Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey | altundag66@yahoo.com
  • Kadri Altundag
    Department of Medical Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey

Abstract

Triple-negative breast cancer is defined by the lack of estrogen receptor, progesterone receptor and HER2 expression with immunohistochemical analysis. Triplenegative breast cancers are poorly differentiated, characterized by high histological grade and occur at a younger age. Treatment options are limited as these tumors are naturally resistant to existing targeted therapies, i.e., endocrine treatment and trastuzumab. An improved understanding of the biology of TNBC has led to evaluation of DNA-damaging chemotherapy drugs and targeted agents, including poly (ADP-ribose) polymerase inhibitors, epidermal growth factor receptor inhibitors, angiogenesis inhibitors, etc., in the treatment of TNBC. This review focuses on outlining the current and emerging treatment options in patients with triple-negative breast cancer.

Keywords

Breast cancer - Triple-negative - Basal-like - Treatment

Full Text:

FULL TEXT
Submitted: 2011-12-05 10:36:50
Published: 2011-12-05 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
582

Views:
FULL TEXT
185

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2011 Omer Dizdar, Kadri Altundag

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185